Sponsored content brought to you by

Isoplexis logo

Chimeric antigen receptor (CAR-T) therapies have shown promise in targeting difficult-to-treat cancers; however, predicting the efficacy, durability, and response of these therapies remains a challenge. Complications such as adverse immune responses, antigen escape, and insufficient immune activation can decrease the efficacy of CAR-T therapies and create hurdles in product development and manufacturing.

Due to these challenges, better methods of product quality analysis are needed to develop novel CAR-T therapies with improved antitumor activity and decreased toxicity.1

IsoPlexis’ Functional Cell Library Provides Insight into Predictive Superhero CAR-T Therapies

IsoPlexis developed a new library of cells characterized by functional proteomics to complement the Genomic Cell Atlas. The Functional Cell Library (functionalcelllibrary.org) adds a unique layer of proteomic data on the wide range of superpowered immune and tumor cell types uniquely identified by IsoPlexis’ Single-Cell Functional Proteomics. The expansion of the superhero library is driven by peer-reviewed publications showing advancements toward human health.

Because immune cells have a wide range of functions, characterizing each individual cell is critical. Polyfunctional cells are the “superhuman” cells of the body, as they drive key processes and correlate with biomarkers such as therapeutic response, product quality, and durability. IsoPlexis’ platform has the unique ability to identify and analyze these superhuman polyfunctional cell subsets, revealing critical functional cellular attributes that can help optimize cell therapies and improve manufacturing methods.

The Functional Cell Library provides the missing insights into the mechanisms driving in vivo biology required to help accelerate the development pipeline and get the product into the clinic, and to the patient, faster.

Single-Cell Analysis Helps Improve Clinical Outcomes and Identify Early Indicators of Response and Relapse

Several high-impact publications have demonstrated how IsoPlexis’ technology captures and connects powerful superhero biology and accelerates advanced therapeutic development.

In a recently published study in Nature Medicine, researchers identified early indicators of response or relapse following CAR-T therapy for large B-cell lymphoma (LBCL). The data from the trial suggested that progressive disease after CD19-22.BB.z-CAR therapy in LBCL is associated with a robust early response followed by early acquired resistance. Researchers identified a functional driver of relapse, which could lead to the development of more effective therapies in the future. IsoPlexis’ unique single-cell functional proteomics provided researchers with meaningful product quality insights to predict CAR-T potency in vivo. The study highlights how IsoPlexis is providing critical predictive metrics for the product characterization and optimization of CAR-T therapies and manufacturing workflows.2

Superhuman Cells for Optimized CAR-T Manufacturing

The ability to measure the direct function of single cells is crucial to predicting disease progression, cell therapy quality, and more. IsoPlexis’ functional proteomics is providing critical product quality metrics in the development of CAR-T therapies, through the discovery of powerful superhero cells. With IsoPlexis’ Functional Cell Library, researchers can now uncover the unique polyfunctional superhero drivers of immune response, accelerating the development of more potent and durable CAR-T therapies.


To learn more about how single-cell proteomics helps researchers optimize cell therapy development, download our eBook “Optimizing Cell & Gene Therapy Development with Single-Cell Functional Proteomics

1. Sterner, R.C., Sterner, R.M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
2. Spiegel, J.Y., Patel, S., Muffly, L. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27, 1419–1431 (2021).


Previous articleAutomating Aseptic Manufacturing of Autologous T-Cell Therapies
Next articleTop 25 Biotech Companies of 2022